Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856088 | 0.82 | NR3C1 (0.47) | TSHRKDM4EALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL12930943 | 0.79 | TMEM97 (0.42) | NR1H2NR1H3TSHRKDM4EALDH1A1 | |
| SCHEMBL15384643 | 0.79 | NR3C1 (0.49) | NR1H2NR1H3TSHRKDM4EALDH1A1 | |
| SCHEMBL1906063 | 0.76 | G6PC1 (0.39) | NR1H2NR1H3TSHRALDH1A1CYP2C19 | |
| SCHEMBL11299583 | 0.72 | TSHR (0.38) | TSHRKDM4EALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL9634037 | 0.71 | CYP3A4 (0.64) | NR1H3ALDH1A1SMN1; SMN2CYP3A4NR3C1 | |
| SCHEMBL7148219 | 0.70 | TSHR (0.54) | TSHRKDM4EALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL11271139 | 0.70 | CYP2C19 (0.64) | NR1H2NR1H3TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL28842673 | 0.70 | TSHR (0.45) | TSHRKDM4EALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL30977574 | 0.69 | ACHE (0.41) | TSHRKDM4ESMN1; SMN2HTTNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| CN-101730695-A | Aminoacyl prodrugs as an active pharmaceutical ingredient for thromboembolic disorders | BAYER HEALTHCARE AG | 2010-06-09 | — | — | CN | disclosed |
| WO-2008155034-A1 | SUBSTITUTED OXAZOLIDINONES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | XDH, OXA1L, PPOX | NR1H2 424/4885NR1H3 359/4885TSHR 4286/4885 |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | AADAC, AADAT, AASDHPPT | NR1H2 2792/4885NR1H3 2556/4885TSHR 3848/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | NR1H2 1791/4885NR1H3 1622/4885TSHR 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.